Arena Pharmaceuticals (ARNA) Lifts Ahead of Tomorrow's BELVIQ Launch
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Arena Pharma (ARNA) BELVIQ Available in U.S. on June 11th
June 7, 2013 8:06 AM EDTArena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported on the launch of BELVIQ (pronounced BEL-VEEK) in the United States. BELVIQ will be available to patients by prescription in US pharmacies beginning June 11. Eisai Inc. is responsible for the marketing and distribution of BELVIQ under its agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc.
BELVIQ is approved by the US Food and Drug Administration for use as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass... More
This Week's BELVIQ Launch Has Arena (ARNA) in the Cross-hairs
June 4, 2013 12:13 PM EDTTraders are on notice to keep a close eye Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) this week, ahead of the launch its key obesity drug BELVIQ on Friday, June 7th.
Arena partner Eisai is responsible for the marketing and distribution of BELVIQ in the U.S. Under the marketing and supply deal with Eisai, Arena will receive a $65 million in milestone payments upon launch. Arena... More
